Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Annals of the Rheumatic Diseases 2007;66(Supplement 3 ):iii87-iii90; doi:10.1136/ard.2007.078527
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oukka, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Oukka, M.

NOVEL TARGETS III

Interplay between pathogenic Th17 and regulatory T cells

Mohamed Oukka

Correspondence to:
Mohamed Oukka, Center for Neurologic Diseases, Brigham and Women’s Hospital Harvard Medical School, Boston, MA 02115, USA; moukka{at}rics.bwh.harvard.edu

Autoimmune diseases arise from a break in tolerance toward self-antigens and are characterised by the development of pathogenic T cell populations infiltrating the target organ. Regulatory T cells play an important role in maintaining self-tolerance through their inhibitory functions on effector T cells. The usage of ex vivo-generated regulatory T cells (Treg) has been regarded as a potentially attractive therapeutic approach for autoimmune diseases. However, the dynamics of Treg in autoimmunity are not well understood. Here, we summarise our published findings on the interplay between Treg and Th17 effector cells in vivo during experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. We have developed Foxp3gfp "knock-in" mice and myelin oligodendrocyte glycoprotein (MOG)35–55/IAb (MHC class II)-tetramers to track autoantigen-specific Treg in vivo during EAE. On immunisation with MOG, Treg cells were detected in the central nervous system (CNS) as early as day 10. However, at the onset of disease, the accumulation of MOG-specific effector T cells (T-eff) largely prevailed. Subsequently, during remission T-eff rapidly contracted whereas a highly suppressive Treg population persisted in the CNS. The interplay between effector Th17 and Treg extend beyond their functions in vivo as we and others have identified the factors responsible for Th17 differentiation. While TGF-β is a critical differentiation factor for Treg cells, IL6 completely inhibits the generation of Treg cells induced by TGF-β. Instead, IL6 and TGF-β together induce the differentiation of pathogenic Th17 cells. Our data demonstrate a dichotomy in the generation of Th17 cells that induce autoimmunity and Treg cells that inhibit autoimmune tissue injury.


Abbreviations: EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; T-eff, effector T cells; Treg, regulatory T cells




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Xiao, H. Jin, T. Korn, S. M. Liu, M. Oukka, B. Lim, and V. K. Kuchroo
Retinoic Acid Increases Foxp3+ Regulatory T Cells and Inhibits Development of Th17 Cells by Enhancing TGF-{beta}-Driven Smad3 Signaling and Inhibiting IL-6 and IL-23 Receptor Expression
J. Immunol., August 15, 2008; 181(4): 2277 - 2284.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism